Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen

21 Jul 2020

Abstract excerpt

Since its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic within a matter of months. While subunit vaccines are one of the prominent options for combating coronavirus disease 2019 (COVID-19), the immunogenicity of spike protein-based antigens remains unknown. When immunized in mice, the S1 domain induced much higher IgG and IgA antibody...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32691875
DOI: 10.1002/jmv.26320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigenPMID 32691875Read ↗

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.Semantic proximity Read ↗

Efficacy of ancestral receptor-binding domain, S1 and trimeric spike protein vaccines against SARS-CoV-2 variants B.1.1.7, B.1.351, and B.1.617.1Semantic proximity Read ↗

Prophylactic domain-based vaccine against SARS-CoV-2, causative agent of COVID-19 pandemicSemantic proximity Read ↗

The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 PandemicSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccinesSemantic proximity Read ↗

Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccineSemantic proximity Read ↗

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesSemantic proximity Read ↗

Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infectionSemantic proximity Read ↗

Preclinical Immunological Evaluation of an Intradermally Administered Heterologous Vaccine Against SARS-CoV-2 VariantsSemantic proximity Read ↗

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccinationSemantic proximity Read ↗

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.